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Genome-wide common and rare variant analysis provides
novel insights into clozapine-associated neutropenia
SE Legge1, ML Hamshere1, S Ripke2,3,4, AF Pardinas1, JI Goldstein2,5, E Rees1, AL Richards1, G Leonenko1, LF Jorskog6,
Clozapine-Induced Agranulocytosis Consortium17, KD Chambert2,3,5,7, DA Collier8,9, G Genovese3, I Giegling10, P Holmans1,
A Jonasdottir11, G Kirov1, SA McCarroll3,12, JH MacCabe13, K Mantripragada1, JL Moran3, BM Neale2,3, H Stefansson11,
D Rujescu10,14, MJ Daly2,3, PF Sullivan6,15,16, MJ Owen1, MC O’Donovan1 and JTR Walters1
The antipsychotic clozapine is uniquely effective in the management of schizophrenia; however, its use is limited by its potential to
induce agranulocytosis. The causes of this, and of its precursor neutropenia, are largely unknown, although genetic factors have an
important role. We sought risk alleles for clozapine-associated neutropenia in a sample of 66 cases and 5583 clozapine-treated
controls, through a genome-wide association study (GWAS), imputed human leukocyte antigen (HLA) alleles, exome array and
copy-number variation (CNV) analyses. We then combined associated variants in a meta-analysis with data from the Clozapine-
Induced Agranulocytosis Consortium (up to 163 cases and 7970 controls). In the largest combined sample to date, we identiﬁed
a novel association with rs149104283 (odds ratio (OR) = 4.32, P= 1.79 × 10− 8), intronic to transcripts of SLCO1B3 and SLCO1B7,
members of a family of hepatic transporter genes previously implicated in adverse drug reactions including simvastatin-induced
myopathy and docetaxel-induced neutropenia. Exome array analysis identiﬁed gene-wide associations of uncommon
non-synonymous variants within UBAP2 and STARD9. We additionally provide independent replication of a previously identiﬁed
variant in HLA-DQB1 (OR= 15.6, P= 0.015, positive predictive value = 35.1%). These results implicate biological pathways through
which clozapine may act to cause this serious adverse effect.
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INTRODUCTION
Clozapine is the only licensed medication for treatment-resistant
schizophrenia, deﬁned as a failure to respond to at least two
antipsychotic trials of sufﬁcient dose and duration. Although it is
the only treatment with proven efﬁcacy in this severely impaired
group of patients,1,2 it is substantially under-prescribed3 due,
at least in part, to the risk of haematological side effects of
agranulocytosis and neutropenia (that is, reductions of neutrophils
to levels below 500 or 1500 mm−3, respectively). The cumulative
risk of agranulocytosis in those taking clozapine is 0.8% and for
neutropenia is 2.9%.4 If undetected, compromised immune
function secondary to agranulocytosis can be fatal, as happened
in a series of patients when the drug was introduced in the 1970s,
leading to its widespread withdrawal. Evidence of its marked
effectiveness over other antipsychotics led to Federal Drug
Agency (USA) approval in 1989 with stipulations about the need
for regular blood monitoring to aid early detection of blood
abnormalities. The requirement for blood monitoring limits the
acceptability of the drug to patients, and poses an obstacle to its
use in clinical practice.5
The aetiology of clozapine-induced blood disorders is currently
unknown, although genetic causes contribute. The ﬁrst genome-
wide association study (GWAS) conducted by the Clozapine-Induced
Agranulocytosis Consortium (CIAC) has provided substantial evi-
dence for the role of HLA-DQB1 and HLA-B in clozapine-associated
neutropenia.6 In this study we report analyses incorporating GWAS,
human leukocyte antigen (HLA) allele imputation, exome array and
copy-number variation (CNV) to examine genetic associations with
clozapine-associated neutropenia. Associated variants were com-
bined in a joint meta-analysis with data from the CIAC study,6 giving
the largest combined study sample of its kind to date.
MATERIALS AND METHODS
Sample description
Study individuals were from CLOZUK (n=5493) and CardiffCOGS (Cognition
in Schizophrenia, n=156) samples. All had clinical or research diagnoses of
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schizophrenia.7 CLOZUK comprises individuals who were prescribed
clozapine in the United Kingdom and have a clinical diagnosis of
treatment-resistant schizophrenia.7,8 The CLOZUK samples were acquired
anonymously by the research team, in accordance with ethics permissions
and the UK Human Tissue Act, in collaboration with Novartis, one of the UK
suppliers of clozapine. Twelve months after sample acquisition, the research
team was informed of those who had developed neutropenia while taking
clozapine and, where available, the recorded lowest neutrophil counts of
these individuals were supplied. CardiffCOGS is a schizophrenia sample
recruited from secondary mental health services in South Wales, UK; for
detailed sample description see.8,9 As part of a comprehensive clinical
interview, individuals were asked about lifetime clozapine use and
occurrence of neutropenia. Clinical case notes were used to conﬁrm
neutropenia status, and lowest recorded neutrophil levels were collected.
Clozapine-associated neutropenia cases (n=66) developed an absolute
neutrophil count (ANC) ⩽1500 mm−3 during treatment with clozapine.
Following the approach of recent studies,6,10 we assessed cases with
neutropenia because the success of the monitoring system and preemptive
drug withdrawal in the United Kingdom has made agranulocytosis extremely
rare. This neutrophil count threshold is used in the United Kingdom as a
trigger to discontinue clozapine. Controls (n=5583) had received clozapine
for a minimum of a year without developing an ANC o2000 mm−3. Those
who had a test result (1500 mm−3oANCo2000 mm−3) were excluded
from all analyses (n=20). No differences in age or sex were observed
between clozapine-associated neutropenia cases and controls (Supple-
mentary Table 1). All individuals were of European ancestry, as determined
by self-report and principal component analysis (PCA) of GWAS data.
Genotyping
Genotyping was performed at the Broad Institute, Cambridge, MA, USA.
CardiffCOGS and part of the CLOZUK sample (40 cases and 3573 controls)
were genotyped on Illumina HumanOmniExpressExome-8v1 and the
remainder of the CLOZUK sample (26 cases and 2098 controls) were
genotyped on both Illumina HumanOmniExpress-12v1 and Illumina
HumanExome BeadChip (San Diego, CA, USA).
Genome-wide association study
Quality-control procedures and imputation were conducted using the
Psychiatric Genomics Consortium pipeline.7 Imputation was performed
using IMPUTE2 (ref. 11) and a reference panel from the full 1000 Genomes
Project data set (freeze date August 2012, see Supplementary Methods).
Principal component estimation was conducted using EIGENSTRAT to
exclude outliers and assess population stratiﬁcation12 (Supplementary
Figures 1 and 2). We included genotyping array as well as the ﬁrst
three principal components as covariates to account for population
structure. Single-nucleotide polymorphisms (SNPs) with allele frequencies
that differed between genotyping arrays at Po1×10−5 were excluded
(Supplementary Figure 3). We selected common SNPs for analysis with high
imputation quality (imputation INFO score≥ 0.8, minor allele frequency
(MAF) ≥0.01 in cases and controls). Association analysis was performed
using logistic regression in PLINK13 and SNPs functionally annotated using
the Scripps genome advisor.14 PLINK13 was used to identify index SNPs in
relative linkage equilibrium. Further details of quality-control procedures and
statistical analyses are provided in Supplementary Methods.
HLA analysis
Classical HLA alleles and amino-acid polymorphisms were imputed using
SNP2HLA (version 1.02)15 using BEAGLE (version 3.0.4)16 from genotyped
common variants using a reference data set of 5225 individuals from Type 1
Diabetes Genetics Consortium (T1DGC). We used the same procedures
for SNP selection, analysis and covariate selection (three PCAs derived from
GWAS, plus genotyping array) as described for the GWAS analysis above.
Owing to complex and extended linkage disequilibrium (LD) in the major
histocompatibility complex, we did not identify index SNPs in relative
linkage equilibrium.
We additionally genotyped a candidate SNP, HLA-DQB1 6672G4C
(ref. 17; rs113332494) in 60 cases and 305 age- and sex-matched controls.
This SNP was genotyped separately as it was not imputed with sufﬁcient
quality to be reported in the GWAS or HLA analyses, and was a strong
candidate variant.17 Genotyping was conducted at deCODE genetics using
the Centaurus (Nanogen) platform.18 Association with clozapine-associated
neutropenia was tested using Fisher’s exact test, given low minor allele
counts; however, to ensure there was no effect of population stratiﬁcation,
we also conducted a logistic regression including three PCAs derived from
GWAS with 5 × 108 permutations to generate empirical P-values.
Exome array analysis
The Illumina exome array is designed to genotype uncommon-to-rare coding
variants previously observed in whole-exome sequencing studies. Exome
array data were available for 57 cases and 4958 exposed controls. Full
details of the quality-control procedures are provided in an open access
publication19 and Supplementary Methods. PCA was conducted using
EIGENSTRAT,12 with 14 743 common exome array variants in relative linkage
equilibrium (MAF⩾0.05, r2o0.2) to assess population structure and identify
outliers (Supplementary Figure 4). Owing to the relatively small case sample
size in our study we did not apply a frequency ﬁlter to variants in this analysis.
Single variant association was conducted using logistic regression in PLINK
with the ﬁrst 10 principal components included as covariates. Adaptive
permutations (between 10 and 1×109) were used to generate empirical
P-values in logistic regression analyses. PLINK13 was used to identify index
SNPs in relative linkage equilibrium. To test for the effects of multiple func-
tional variants in genes, we used SKAT-O (ref. 20) with 2×106 permutations,
including the ﬁrst 10 principal components, for genes with at least two
uncommon (MAFo0.05), non-synonymous (missense, stop or splice) variants.
Copy-number variation
The identiﬁcation and quality control of CNV for this sample has been
previously described8 and is detailed in Supplementary Methods. CNVs
were included if they had a frequency ⩽ 0.01, contained ⩾ 10 probes and
were ⩾ 100 kb in length. Samples that passed both CNV and GWAS quality
control (63 cases and 5456 controls) were used to test genes for
enrichment of exon disrupting CNVs using a two-sided Fisher’s exact test.
Deletions and duplications were analysed separately.
Secondary analysis of clozapine-associated neutropenia below
⩽ 1000 mm−3
We conducted secondary analyses on a subset of the more severely
affected cases with ANC ⩽ 1000 mm−3 (n= 18). A total of four of these
cases had developed agranulocytosis (ANC ⩽ 500 mm− 3). We assessed the
association of single variants with clozapine-associated neutropenia below
⩽ 1000 mm−3 in GWAS (N= 18), exome array (N=16) and HLA imputation
(N= 18) analyses. All analyses conducted were consistent with methods
used for clozapine-associated neutropenia, described above.
Replication sample and meta-analysis
We obtained summary statistics for associated SNPs from a recently
published study by the CIAC.6 In this study, Goldstein et al.6 conducted a
comprehensive genetic association study in 163 clozapine-induced neutro-
penia cases (98 with ANC o500 mm−3, 61 with 500⩽ANC⩽ 1000 mm−3
and 4 with ANC ⩽1500 mm−3). The CIAC study included the following:
GWAS (161 cases with clozapine-induced neutropenia, 249 clozapine-
exposed controls without neutropenia and 947 unexposed controls), exome
array analysis (148 cases and up to 7970 unexposed controls) and classical
HLA allele imputation (162 cases and 4319 unexposed controls). These data
sets formed the replication samples for the current study and were
combined with results for both (i) clozapine-associated neutropenia and (ii)
neutropenia ⩽ 1000 analyses. SNPs that were associated with clozapine-
associated neutropenia at Po1×10− 4 from our GWAS, or Po0.05 from our
HLA variant analysis, were combined with the replication data in ﬁxed-
effects meta-analyses using PLINK to estimate a combined odds ratio (OR)
weighted by the study’s inverse standard error (s.e.). If an index SNP was not
present in the replication data, a proxy SNP in strong LD (r2⩾ 0.8) was
substituted and the s.e. weighted (s.e.w.) to account for the lack of
information: s.e.w. = s.e./sqrt(r2).21 The variants that were associated with
clozapine-associated neutropenia from exome array analyses with Po0.01
were combined with the replication data in a P-value-based method in
METAL,22 weighted by the square root of the total sample size. We used
different P-value replication thresholds for the HLA and exome array to arrive
at approximately the same number of variants.
RESULTS
Figure 1 provides a summary of the study design and key results
from each analysis.
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Genome-wide association study
We performed a GWAS of 7 559 010 genotyped and imputed
common SNPs (QQ plot in Supplementary Figure 5, λGC = 0.95).
Two SNPs were associated with clozapine-associated neutropenia
at the genome-wide signiﬁcant level of Po5 × 10− 8 (Supple-
mentary Figure 6 and Supplementary Data 1); rs80208670 on
chromosome 13 (OR= 8.76, 95% conﬁdence interval (CI): 4.21–
18.25, P= 6.51 × 10− 9) and rs77897117 on chromosome 1 (OR=
4.02, 95% CI: 2.46–6.57, P= 4.60 × 10− 8). Our sample size had
80% power to detect an OR44 for alleles with MAF40.10
at Po5 × 10− 8 (Supplementary Figure 7). The genome-wide
signiﬁcant SNPs from the discovery CLOZUK GWAS, rs80208670
and rs77897117, were not signiﬁcantly associated in CIAC (OR=
1.69, P= 0.27 and OR= 0.67, P= 0.28, respectively).
In total, there were 266 independent (r2o0.1) SNPs associated
with clozapine-associated neutropenia at Po1 × 10− 4 and we
sought replication of these SNPs in the CIAC sample (257 of these
SNPs were available or had an appropriate proxy, Supplementary
Data 1). Table 1 lists the 10 most strongly associated SNPs
from the meta-analysis. One SNP on chromosome 12 surpassed
the GWS threshold for association with clozapine-associated
neutropenia (OR = 4.32, P= 1.79 × 10− 8). rs149104283 is intronic
to transcripts of SLCO1B3 and SLCO1B7 (solute carrier organic
anion transporter family, member 1B3 and member 1B7) and was
present in 7.37% of cases versus 1.52% of controls in our sample
and 4.20% of cases versus 1.67% of controls in the CIAC sample.
For consideration of how this may be translated to risk allele
carrier status see Supplementary Results.
HLA analysis
No imputed classical HLA allele or amino-acid polymorphism was
associated with clozapine-associated neutropenia at the genome-
wide signiﬁcant level (Po5 × 10− 8) in either the discovery analysis
(SNPs = 7751) or combined meta-analysis (SNPs = 102; Supple-
mentary Data 2). It was not possible to impute the amino-acid
polymorphisms HLA-DQB1 (126Q) and HLA-B (158T) implicated in
the CIAC study6 with sufﬁcient quality (INFO40.8) in the discovery
sample.
We additionally genotyped a previously associated variant, HLA-
DQB1 6672G4C 17 (rs113332494), in 60 cases and 305 age- and
sex-matched controls as it was not imputed with sufﬁcient quality.
We found independent support for association of HLA-DQB1
6672G4C (OR= 15.6, 95% CI: 1.6–151.4, P= 0.015), replicating
previous reports of association with clozapine-induced agranulo-
cytosis.17 The association strengthened when considering only
those with ANC below ⩽ 1000 mm−3 (OR= 38.1, 95% CI: 3.4–430.9,
Figure 1. Study design and key results. To investigate the association of genetic variants with clozapine-associated neutropenia, we conducted
(a) a genome-wide association study (GWAS), (b) human leukocyte antigen (HLA) allele imputation and genotyped a candidate variant of
interest, HLA-DQB1 6672G4C/ rs113332494, (c) exome array single variant and gene-based analysis and (d) copy-number variation (CNV)
analysis. We then took forward the associated variants from GWAS, HLA and exome array analyses to a combined meta-analysis with the
Clozapine-Induced Agranulocytosis Consortium (CIAC) study.
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P= 0.0079). For the associated ‘G’ allele, we found three
heterozygote carriers among 60 cases, and a single heterozygote
in 305 controls. Lowest neutrophil counts were available for two
of the three ‘G’ case carriers, both of whom had a neutrophil
level o1000 mm−3 (700 and 900). The association remained
after adjusting for GWAS PCAs. For further consideration of
possible population-speciﬁc effects at this locus please refer to
Supplementary Results.
Exome array analysis
In exome array analyses, no single variant exceeded a signiﬁ-
cance threshold of Po4.3 × 10− 7, corresponding to a Bonferroni
correction for 115 000 variants tested, in either the discovery or
combined meta-analyses (Supplementary Data 3, QQ plot given in
Supplementary Figure 8, λGC = 1.11). Table 2 lists the 10 most
strongly associated exome variants from the meta-analysis. Of
interest is rs1546308 (P= 1.10 × 10− 6), a missense variant in
SLCO1B7 and intronic to SLCO1B3, that is 92 kb from the SNP
that emerged as the only genome-wide signiﬁcant variant from
GWAS meta-analysis. rs1546308 is predicted to be benign and was
present in 15.8% of cases versus 5.8% of controls in our sample
and 9.3% of cases versus 5.6% of controls in the CIAC sample.
Supplementary Table 3 displays the 10 most signiﬁcantly
associated genes (including the total allele count and number of
variants contributing to each gene) based on the SKAT-O analysis
of genes with at least two uncommon (MAFo0.05), non-
synonymous variants from the exome array. There was evidence
of association for two genes that exceeded a threshold of
Po2.5 × 10− 6 (corresponding to a Bonferroni correction of 20 000
genes tested;23 QQ plot in Supplementary Figure 9): UBAP2 on
chromosome 9 (P= 1.02 × 10− 7) and STARD9 on chromosome 15
(P= 2.85 × 10− 7). Owing to differing analytical methods used
by CIAC, it was not possible to combine our gene-based results
in a joint analysis (see Supplementary Methods for detailed
explanation).
Copy-number variation
In a genome-wide analysis, no individual gene was signiﬁcantly
enriched for large, rare exonic CNVs that exceeded a signiﬁcance
threshold of Po2.5 × 10− 6 (Supplementary Data 4).
Associations with rs1546308 and rs149104283 are not
independent
We investigated the independence of rs1546308 (missense variant
in SLCO1B7 and intronic in SLCO1B3 from exome chip analysis) and
rs149104283 (GWAS intronic variant in SLCO1B3 and SLCO1B7) in
samples with data available for both variants (55 cases and 4834
controls). The LD between the two variants in the sample
was r2 = 0.15, D’= 0.84. In a conditional logistic regression, the
strength of the association of rs1546308 with clozapine-associated
Table 1. GWAS meta-analysis top 10 SNPs
CHR SNP Position A1 CLOZUK CIAC Meta-analysis Nearest gene Location
P-value OR INFO P-value OR INFO P-value OR
12 rs149104283 21 083 862 T 4.98 × 10− 7 6.20 0.87 3.61 × 10− 3 2.95 0.87 1.79 × 10− 8 4.32 SLCO1B3, SLCO1B7 Intronic, intronic
13 rs80208670 84 438 088 C 6.51 × 10− 9 8.76 0.83 0.2728 1.69 0.83 1.56 × 10− 7 4.69 SLITRK1 13 kb Downstream
1 rs184597564 82 236 406 A 2.48 × 10− 5 4.03 0.89 4.99 × 10− 3 2.40 0.94 8.01 × 10− 7 3.06 ADGRL2 Intronic
7 rs78900159 76 968 378 A 6.94 × 10− 6 4.01 0.99 0.0247 1.97 0.98 2.02 × 10− 6 2.79 GSAP Intronic
10 rs16916041 63 146 547 T 7.40 × 10− 6 2.57 1.02 0.0205 1.58 0.96 2.05 × 10− 6 1.98 TMEM26 20 kb Downstream
16 rs11649311 25 226 020 T 9.70 × 10− 5 2.07 0.89 2.62 × 10− 3 1.51 0.89 2.26 × 10− 6 1.68 AQP8 2 kb Upstream
17 rs117202297 53 769 035 T 8.48 × 10− 6 6.25 0.82 0.1503 2.66 0.66 5.27 × 10− 6 4.97 TMEM100 28 kb Downstream
17 rs80282661 13 252 073 T 1.99 × 10− 6 6.15 0.90 0.2632 1.85 0.89 5.49 × 10− 6 4.17 HS3ST3A1 147 kb Downstream
1 rs185053659 60 704 250 A 7.76 × 10− 6 5.80 0.86 0.1012 2.13 0.92 8.05 × 10− 6 3.80 C1orf87 165 kb Upstream
14 rs78074145 40 404 458 C 1.13 × 10− 6 4.05 0.96 0.2716 1.44 0.99 1.08 × 10− 5 2.60 FXB033 503 kb Upstream
Abbreviations: A1, minor reference allele; CHR, chromosome; CIAC, Clozapine-Induced Agranulocytosis Consortium; GWAS, genome-wide association study;
OR, odds ratio; SNP, single-nucleotide polymorphism. Results are ordered by meta-analysis P-value. Further details, including minor allele frequencies, are
available in Supplementary Data 1.
Table 2. Exome array meta-analysis top 10 variants
CHR Variant rs ID Position A1 CLOZUK
P-value
CIAC P-value Meta-analysis
P-value
Gene Location Function
4 exm387558 rs201099591 7 436 363 A 2.48× 10− 3 1.31× 10− 4 1.10 × 10− 6 PSAPL1,
SORCS2
Exonic,
intronic
Missensea
7 exm622984 rs17139320 63 726 370 G 3.96× 10− 3 2.87× 10− 4 3.70 × 10− 6 ZNF679 Exonic Missensea
8 exm729894 rs201071539 145 003 862 A 2.19× 10− 3 1.69× 10− 3 1.19 × 10− 5 PLEC Exonic Missensea
19 exm1421170 rs2591594 9 076 728 A 4.66× 10− 3 3.26× 10− 3 4.52 × 10− 5 MUC16 Exonic Missenseb
12 exm988839 rs1546308 21 176 135 C 1.25× 10− 4 0.0679 9.13 × 10− 5 SLCO1B7,
SLCO1B3
Exonic,
intronic
Missensea
1 exm23767 rs12073549 17 720 545 T 1.60× 10− 3 0.0163 9.31 × 10− 5 PADI6 Exonic Synonymous
15 exm1186658 rs117116488 89 390 513 T 2.76× 10− 4 0.0448 9.73 × 10− 5 ACAN Exonic Missenseb
12 exm981950 rs79149293 8 975 873 G 5.66× 10− 5 0.0967 1.01 × 10− 4 A2ML1 Exonic Missensec
12 exm995289 rs138912646 42 711 606 A 3.94× 10− 5 0.1613 1.79 × 10− 4 ZCRB1,
PPHLN1
Exonic,
intronic
Missensea
12 exm1051374 rs143584336 130 921 539 A 1.22× 10− 4 0.1144 2.12 × 10− 4 RIMBP2 Exonic Missensea
Abbreviations: A1, minor reference allele; CHR, chromosome; CIAC, Clozapine-Induced Agranulocytosis Consortium. Results are ordered by meta-analysis
P-value. Predicted function of non-synonymous variants. aBenign. bPossibly damaging. cProbably damaging. Further details, including minor allele frequencies,
are available in Supplementary Data 3.
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neutropenia was attenuated from OR=3.00 (95% CI: 1.735–5.189,
P= 8.40 × 10− 5) to OR= 2.16 (95% CI: 1.093–4.251, P= 0.027) after
adjusting for rs149104283. Haplotype analysis did not strengthen
the association signal. Thus, these two ﬁndings are not
independent, and the associated region spans SLCO1B1, SLCO1B3
and SLCO1B7 (Figure 2 and Supplementary Figure 14).
Secondary analysis of clozapine-associated neutropenia below
⩽ 1000 mm−3
Results of the GWAS for the more stringent neutropenia cutoff
of ⩽ 1000 mm−3 are presented in Supplementary Results. The
combined GWAS meta-analysis identiﬁed no loci exceeding
genome-wide signiﬁcance. The genome-wide signiﬁcant SNP
from the GWAS meta-analysis, rs149104283, had a MAF of 7.8%
in cases with ANC ⩽ 1000 mm− 3, and was associated at OR= 7.6,
P= 0.0027 in the discovery sample. No variants exceeded relevant
signiﬁcance thresholds in imputed HLA and exome array discovery
or combined meta-analyses (see Supplementary Results).
DISCUSSION
We have conducted a multifaceted genetic analysis of clozapine-
associated neutropenia in the largest combined sample studied to
date. Using GWAS, we identify a novel association implicating
a family of organic anion transporters involved in drug metabo-
lism, which have been previously associated with adverse drug
reactions. We also found evidence for effects of uncommon non-
synonymous variants within UBAP2 and STARD9 and provide
independent replication of a previously identiﬁed variant in
HLA-DQB1.
The primary GWAS ﬁnding from the meta-analysis was
a genome-wide signiﬁcant association with neutropenia for
rs149104283. The association effect size of this polymorphism
is larger in the CLOZUK discovery sample (OR = 6.2) than in the
CIAC replication data set (OR= 2.95), as would be expected from
winner’s curse. It follows that the true effect size probably lies
closer to the CIAC estimate, although this requires conﬁrmation
using independent data. rs149104283 is an intronic SNP for
transcripts of both SLCO1B3 and SLCO1B7—the associated region
containing a third member of this organic anion transporter
family, SLCO1B1. SLCO1B7 encodes a putative protein (OAT1B7)
that is poorly characterised, based on coding sequence prediction,
and its functionality is unknown. SLCO1B3 and SLCO1B1 share
sequence homology and encode liver-speciﬁc organic anion
transporter polypeptides (OATP1B3 and OATP1B1) that are
multipass transmembrane proteins expressed exclusively in the
basolateral membrane of hepatocytes.24 They facilitate uptake of
exogenous substances, including drugs, from the portal vein into
hepatocytes, where the substance is subsequently modiﬁed either
via metabolism with cytochrome (CYP) 450 enzymes or excreted.25
Polymorphisms in SLCO1B1 and SLCO1B3 have been implicated
in adverse reactions with other drugs. In 2008, a GWAS identiﬁed
a missense variant rs4149056 in SLCO1B1 that increased the
risk of simvastatin-induced myopathy by increasing the area
under the curve for simvastatin, particularly in those taking high
doses.26 This prominent pharmacogenetic ﬁnding has been widely
replicated and has led to recommendations for its use as a routine
preemptive clinical test.27 Particularly relevant to the current study
are reports of an association between rs11045585, an intronic
variant in SLCO1B3, and severe leukopenia/neutropenia induced
by docetaxel, a chemotherapeutic agent,28 and that this may be
secondary to alterations in the pharmacokinetics and bioavail-
ability of the drug.29–31 These polymorphisms were not in high LD
(r2o0.1 for both) with the index SNP in this study, although
rs11045585 was weakly associated with neutropenia in our
discovery sample (OR= 1.62, P= 0.03).
Together, the ﬁndings suggest the hypothesis that genetic
variants at SLCO1B3 (and/or SLCO1B1) increase the risk of
clozapine-associated neutropenia through a pharmacokinetic
mechanism. It is unclear whether clozapine plasma levels are
associated with the development of neutropenia.32–34 One of the
best-supported hypotheses to explain clozapine’s association
with agranulocytosis relates to the bioactivation of clozapine, or
Figure 2. Association of 12p12.2 with clozapine-associated neutropenia. LocusZoom plot of the region associated with clozapine-associated
neutropenia on chromosome 12p12.2 in CLOZUK (discovery) sample. Genes within the region are shown in the lower panel, and the
unbroken blue line indicated the recombination rate within the region. Each circle represents the P-value for one SNP in the discovery sample,
with the top SNP rs149104283 shown in purple and the SNPs in the region coloured depending on their degree of correlation (r2) with
rs149104283 (as estimated by LocusZoom on the basis of CEU HapMap haplotypes).
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a stable metabolite, to a chemically reactive nitrenium ion.35 The
propensity for nitrenium ions to cause apoptosis to neutrophils, or
be toxic to neutrophil precursors, is dose-dependent, lending
support to the hypothesis that clozapine pharmacokinetics and
bioavailability are related to its potential to cause neutropenia.36,37
In analysis of exome chip data we found evidence of association
with neutropenia for uncommon non-synonymous variants in
STARD9 and UBAP2. STARD9 is a mitotic kinesin, and STARD9-
depleted cancer cells have abnormal cellular morphology and
undergo apoptosis.38 In addition, STARD9 depletion was found to
synergise with the chemotherapeutic agent taxol, the use of
which is dose-limited because of neutropenia.38 The function of
UBAP2 is undetermined, although it has an ubiquitin-associated
domain and is widely expressed across tissues including bone
marrow. The ubiquitination pathway has been shown to modulate
the granulocyte colony-stimulating factor receptor,39,40 a critical
regulator of neutrophil production. A recent study reported the
association of a missense variant in the ubiquitin gene USP43 with
clozapine-associated neutropenia.10
Our ﬁnal ﬁnding adds to the growing evidence implicating
HLA-DQB1 in clozapine-associated neutropenia, supporting the
recently published CIAC study.6 There have been further reports
implicating SNPs within HLA-DQB1,17,41,42 although these samples
and those in CIAC are overlapping; thus, we believe we provide
the ﬁrst fully independent replication implicating this locus in
clozapine-associated neutropenia/agranulocytosis. The HLA-DQB1
variant alone has a positive predictive value of 35.1% (see
Supplementary Table 4). Although this is promising, the majority
of those that develop neutropenia or agranulocytosis while taking
clozapine are not carriers of this risk allele, or indeed the other
alleles we have identiﬁed in this study. The sensitivity for a test
including rs149104283 (GWS intronic variant in SLCO1B3 and
SLCO1B7), rs1546308 (missense variant in SLCO1B7) and
rs113332494 (HLA-DQB1) is 29.17%, the speciﬁcity 90.61%, the
positive predictive value 9.94% and the negative predictive value
97.30% (Supplementary Table 4). Although the variants identiﬁed
in this study convey a substantially increased risk for clozapine-
associated neutropenia, they are currently on their own unlikely to
have clinical utility for pharmacogenetic testing,43 particularly as
there is currently no alternative treatment for those with
treatment-resistant schizophrenia.
An important consideration is that the majority of cases in our
analyses had developed neutropenia rather than agranulocytosis.
It is now very rare in the United Kingdom to develop
agranulocytosis because of the success of the monitoring system
and the fact that clozapine is stopped once neutropenia is
detected; in fact, only four cases met this threshold in our sample.
Despite this, we found that the major ﬁndings from our
neutropenia analysis extended to the secondary analyses, which
was restricted to those with an ANC⩽ 1000 mm− 3, indicating that
the clozapine-associated neutropenia ﬁndings are likely to be
applicable to those with severe neutropenia and agranulocytosis.
Our ﬁndings provide novel insights into putative biological
processes underlying clozapine-associated neutropenia. Further-
more, we have indicated a potential link between the pharma-
cokinetics of clozapine and risk of neutropenia/agranulocytosis
with potentially important clinical implications. The development
of such understanding should help widen the availability of
clozapine with a beneﬁcial impact on those with treatment-
resistant schizophrenia.
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